Literature DB >> 15580144

Treatment of gastroesophageal reflux disease: defining endpoints that are important to patients.

Nimish Vakil1.   

Abstract

Patients with gastroesophageal reflux disease (GERD) seek treatment to obtain relief of their symptoms. Symptoms are important to patients because they interfere with activities of daily living and impair quality of life. Clinical trials in GERD have traditionally focused on the healing of erosive esophagitis, and symptom endpoints have been relegated to a secondary role. In primary care, however, patients typically are treated empirically without definition of the presence or absence of esophagitis. Patient-centered endpoints such as complete symptom resolution, patient satisfaction, and improvement in quality of life therefore provide more meaningful results in the broad population of patients with GERD, provided they are coupled with objective data on mucosal healing. This article reviews the importance of patient-centered endpoints in the assessment of the treatment of GERD and concludes that complete resolution of symptoms is the most rigorous endpoint in clinical trials and provides a meaningful endpoint for therapy in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15580144

Source DB:  PubMed          Journal:  Rev Gastroenterol Disord        ISSN: 1533-001X


  4 in total

1.  Validation of the PAGI-SYM and PAGI-QOL among healing and maintenance of erosive esophagitis clinical trial participants.

Authors:  Kathleen W Wyrwich; Reema Mody; Lois M Larsen; Misun Lee; Neesha Harnam; Dennis A Revicki
Journal:  Qual Life Res       Date:  2010-02-27       Impact factor: 4.147

2.  In vitro effect of pantoprazole on lower esophageal sphincter tone in rats.

Authors:  Mustafa Duman; Mahmut Ozer; Enver Reyhan; Yeliz Demirci; Ali E Atıcı; Tahsin Dalgıç; Erdal B Bostancı; Ece Genç
Journal:  World J Gastroenterol       Date:  2011-12-14       Impact factor: 5.742

3.  Quality Of Life in Reflux and Dyspepsia (QOLRAD) Questionnaire in Iranian Patients with GERD: A Validation Study.

Authors:  S Tofangchiha; H Razjouyan; S Nasseri-Moghaddam
Journal:  Middle East J Dig Dis       Date:  2010-09

4.  A phase 1 randomized study evaluating the effect of omeprazole on the pharmacokinetics of a novel 5-hydroxytryptamine receptor 4 agonist, revexepride (SSP-002358), in healthy adults.

Authors:  David Pierce; Mary Corcoran; Maria Velinova; Stuart Hossack; Mieke Hoppenbrouwers; Patrick Martin
Journal:  Drug Des Devel Ther       Date:  2015-02-27       Impact factor: 4.162

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.